Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxidized ATP (oATP) is a chemically modified analog of adenosine triphosphate considered a specific, irreversible antagonist of purinergic P2X7 (formerly known as P2Z) receptors. It covalently modifies these receptors, permanently inhibiting their activation by extracellular ATP. This blockade disrupts processes mediated by P2X7, such as ATP-induced Ca2+ influx, proinflammatory signaling, and membrane permeabilization in immune cells (macrophages and APCs). oATP is frequently used as an experimental tool to dissect purinergic signaling in immunology and inflammation models but is not an approved pharmaceutical. Its immunoregulatory effects include suppressing APC maturation and diminishing T cell-mediated immune responses in transplant models, and it attenuates inflammation in vivo[3][5][9][11][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxidized ATP.